LON:STX Shield Therapeutics (STX) Share Price, News & Analysis GBX 8.20 +1.90 (+30.16%) As of 11:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Shield Therapeutics Stock (LON:STX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Shield Therapeutics alerts:Sign Up Key Stats Today's Range 7.18▼ 8.9050-Day Range 2.70▼ 8.2552-Week Range 2.10▼ 8.90Volume25.56 million shsAverage Volume2.61 million shsMarket Capitalization£85.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics. Read More Receive STX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STX Stock News HeadlinesShield Therapeutics Reports Positive Results for Ferric Maltol in Heart Failure PatientsAugust 27, 2025 | msn.comShield Therapeutics First Half 2025 Earnings: US$0.009 loss per share (vs US$0.02 loss in 1H 2024)August 24, 2025 | finance.yahoo.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 4 at 2:00 AM | Porter & Company (Ad)This 5p penny stock is crushing the stock market in 2025August 18, 2025 | msn.comShield Therapeutics revenue jumps on rising Accrufer prescriptionsJuly 24, 2025 | lse.co.ukShield Therapeutics plc's (LON:STX) Path To ProfitabilityJuly 16, 2025 | finance.yahoo.comShield Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagApril 26, 2025 | uk.finance.yahoo.comShield Therapeutics secures ACCRUFeR® deal in JapanApril 23, 2025 | investing.comSee More Headlines STX Stock Analysis - Frequently Asked Questions How have STX shares performed this year? Shield Therapeutics' stock was trading at GBX 2.70 at the beginning of 2025. Since then, STX shares have increased by 202.5% and is now trading at GBX 8.17. How were Shield Therapeutics' earnings last quarter? Shield Therapeutics plc (LON:STX) posted its quarterly earnings data on Thursday, April, 24th. The company reported ($3.00) earnings per share (EPS) for the quarter. Shield Therapeutics had a negative net margin of 173.43% and a negative trailing twelve-month return on equity of 470.50%. How do I buy shares of Shield Therapeutics? Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS). Company Calendar Last Earnings4/24/2025Today9/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryComputer Hardware Current SymbolLON:STX CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500FaxN/AEmployees40,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.03) Trailing P/E RatioN/A Forward P/E Ratio117.76 P/E GrowthN/ANet Income-£36.28 million Net Margins-173.43% Pretax MarginN/A Return on Equity-470.50% Return on Assets-47.85% Debt Debt-to-Equity Ratio3,691.50 Current Ratio1.05 Quick Ratio2.16 Sales & Book Value Annual Sales£41.50 million Price / Sales2.09 Cash FlowGBX 1.31 per share Price / Cash Flow6.36 Book ValueGBX 0.05 per share Price / Book152.27Miscellaneous Outstanding Shares1,041,690,000Free FloatN/AMarket Cap£86.80 million OptionableNot Optionable Beta1.42 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (LON:STX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.